Compare

Ocular Therapeutix, Inc vs Lexicon Pharmaceuticals, Inc. vs Nektar Therapeutics vs Gossamer Bio, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearOcular Therapeutix, Inc
OCUL
Lexicon Pharmaceuticals, Inc.
LXRX
Nektar Therapeutics
NKTR
Gossamer Bio, Inc.
GOSS
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$51.95M$49.80M$55.23M$48.47M
Revenue growth (YoY)-18.5%+60.2%-43.9%-57.7%
Gross margin87.3% (computed)n/an/an/a
Operating margin-519.8%-98.2%-253.7%-352.2%
Net margin-511.9%-101.1%-297.1%-351.5%
Net income-$265.94M-$50.34M-$164.08M-$170.37M
EPS (Diluted)-$1.42-$0.14-$9.73-$0.75
Operating cash flow-$204.88M-$67.85M-$208.51M-$171.27M
Free cash flow-$216.89M-$67.85M-$208.68M-$171.34M
Cash & equivalents$737.06M$34.33M$15.12M$37.73M
Total assets$808.06M$184.99M$280.41M$172.25M
Total liabilities$153.75M$77.45M$190.57M$295.01M
Shareholders' equity$654.31M$107.54M$89.83M-$122.76M
Return on year-end equity-40.6%-46.8%-182.6%n/a
Shares outstanding215.93M365.85M20.38M233.68M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearOcular Therapeutix, IncLexicon Pharmaceuticals, Inc.Nektar TherapeuticsGossamer Bio, Inc.
Latest$51.95M
Ended 2025-12-31
$49.80M
Ended 2025-12-31
$55.23M
Ended 2025-12-31
$48.47M
Ended 2025-12-31
1 year earlier$63.72M
Ended 2024-12-31
$31.08M
Ended 2024-12-31
$98.43M
Ended 2024-12-31
$114.70M
Ended 2024-12-31
2 years earlier$58.44M
Ended 2023-12-31
$1.20M
Ended 2023-12-31
$90.12M
Ended 2023-12-31
$0
Ended 2023-12-31
3 years earlier$51.49M
Ended 2022-12-31
$139.0K
Ended 2022-12-31
$92.06M
Ended 2022-12-31
$0
Ended 2022-12-31
4 years earlier$43.52M
Ended 2021-12-31
$298.0K
Ended 2021-12-31
$101.91M
Ended 2021-12-31
n/a